Introduction {#s1}
============

Telomeres, a series of tandem repeats of TTAGGG nucleotides, cap the ends of chromosomes in all eukaryotic cells [@pone.0020466-Blackburn1] and maintain genomic stability by prohibiting fatal events, such as nucleolytic degradation, chromosomal end-to-end fusion and irregular recombination [@pone.0020466-Moon1]. Human telomeres are approximately 10--15 kb in somatic cells and progressively shortened by ∼30 to 200 bp after each cycle of mitotic division, due to incomplete replication of linear DNA molecules and the absence of a mechanism for elongation of telomeres [@pone.0020466-Harley1]. When the telomeres reach a critical length, Rb and p53 signaling pathways are triggered to initiate either cell senescence or apoptosis [@pone.0020466-Mathon1]. Thus, telomere length has been suggested as a "cellular mitotic clock" that defines the number of cell divisions and cellular life span [@pone.0020466-Blackburn1], [@pone.0020466-Allsopp1].

Several studies have documented correlations between shortened telomeres and multiple human diseases associated with age, such as Alzheimer\'s disease [@pone.0020466-Panossian1], myocardial infarction [@pone.0020466-Brouilette1], vascular dementia [@pone.0020466-vonZglinicki1], liver cirrhosis [@pone.0020466-Wiemann1], atherosclerosis [@pone.0020466-Benetos1], ulcerative colitis [@pone.0020466-Kinouchi1] and premature aging syndromes [@pone.0020466-Blasco1]. Additionally, telomere shortening is involved in initiation and progression of malignancies in mouse models and functional studies [@pone.0020466-Smogorzewska1], [@pone.0020466-vonZglinicki2]. For example, short telomeres cause an increased risk of developing epithelial cancers by the formation of complex non-reciprocal translocations [@pone.0020466-Blasco2], [@pone.0020466-Artandi1], and telomeres in tumor cells and their precursor lesions are significantly shorter than that in surrounding non-tumor cells [@pone.0020466-Joshua1], [@pone.0020466-Kammori1].

Although evidence from functional studies and animal models support the hypothesis that telomere shortening contributes to tumor development, results from population studies remain conflicting rather than conclusive [@pone.0020466-Wu1]--[@pone.0020466-Idei1]. For instance, several case-control studies have investigated the association between telomere length in peripheral blood lymphocytes and breast cancer risk [@pone.0020466-Shen1], [@pone.0020466-Svenson1], [@pone.0020466-DeVivo1], [@pone.0020466-Shen2], [@pone.0020466-Gramatges1], [@pone.0020466-Zheng1], [@pone.0020466-Pooley1]; some showed that shorter telomeres were associated with increased risk of breast cancer [@pone.0020466-Shen2], [@pone.0020466-Pooley1], while others indicated converse or insignificant associations [@pone.0020466-Shen1], [@pone.0020466-Svenson1], [@pone.0020466-DeVivo1], [@pone.0020466-Gramatges1], [@pone.0020466-Zheng1]. These findings suggest that any of these single studies may have been underpowered to detect the association between telomere length and cancer risk because of their limited sample sizes. Furthermore, the underlying heterogeneity among different studies can be explored in a meta-analysis. Thus, we conducted a systematic meta-analysis on 21 relevant publications with 11,255 cases and 13,101 controls to estimate the overall cancer risk or cancer-specific risk associated with telomere length and to evaluate potential between-study heterogeneity of these published studies.

Materials and Methods {#s2}
=====================

Search strategy and selection criteria {#s2a}
--------------------------------------

We used two electronic databases (MEDLINE and EMBASE) to identify all case-control studies published to date on an association between telomere length and cancer risk (last search update in November, 2010, using the search terms "telomere length", "cancer" or "carcinoma", and "risk"). Additional studies were identified by a hands-on search of references of original studies or reviews on this topic. Authors were also contacted directly, if crucial data were not reported in original papers. Studies included in the current meta-analysis had to meet the following criteria: written in English; case-control design; sufficient information needed to estimate odds ratios (ORs) and their 95% confidence intervals (CIs); independent from other studies to avoid double weighting in the estimates derived from the same study. In addition, investigations in subjects with cancer-prone disposition were excluded from the analysis.

Data extraction {#s2b}
---------------

Two authors (HM and ZZ) independently extracted data and reached a consensus on all of the items. The following information was extracted from each report: the first author, year of publication, country of origin, ethnicity, cancer type, the number of cases and controls grouped by median or quartiles of relative telomere length (T/S ratio), study type, control source (population-based and hospital-based), DNA source, and measurement methods for telomere length. For studies including subjects of different racial descent, data were extracted separately for each ethnic group (categorized as Caucasian, Asian or others). When a study did not state what ethnic groups were included or if it was impossible to separate participants according to the data presented, the sample was termed as 'other populations'. Furthermore, references involved in different ethnic groups, different types of cancer and different institutions were divided into multiple study samples for subgroup analyses.

Quantitative data synthesis {#s2c}
---------------------------

The number of cases and controls grouped by the median of the relative telomere length (T/S ratio) was collected from each study to evaluate the risk of cancers (ORs and 95% CI). For each study, a median value of the relative telomere length (T/S ratio) in controls was considered as a cut-point dividing all subjects into two groups: the longer telomere group and the shorter telomere group. The association between the relative telomere length (T/S ratio) and cancer risk was examined by ORs and 95% CIs with the group of longer telomeres as the reference. The stratification analyses were also conducted by cancer type (if one cancer type was investigated in less than three studies, it would be merged into the 'other cancers' group), study type (retrospective and prospective), ethnicity (Caucasian, Asian or others), control source (hospital-based and population-based) and sample size (\<500, 500--1000 and \>1000). Smoking-related cancers were defined as those of the lung, bladder, head and neck, kidney and pancreas; and cancers of the digestive system included those of the stomach, esophagus and colon. Additionally, cancers arising from the bladder, kidney and prostate sites were considered cancers of the urogenital system.

The χ^2^-based Q test was performed to assess between-study heterogeneity and considered significant if *P*\<0.05 [@pone.0020466-Lau1]. Heterogeneity was also quantified with the *I* ^2^ statistic, a value that indicates what proportion of the total variation across studies is beyond chance, where 0% indicates no observed heterogeneity and larger values show increasing heterogeneity [@pone.0020466-Higgins1]. The fixed-effects model and the random-effects model, based on the Mantel-Haenszel method [@pone.0020466-Mantel1] and the DerSimonian and Laird method [@pone.0020466-DerSimonian1], respectively, were used to combine values from different studies. When *P* value of the heterogeneity test was ≥0.05, the fixed-effects model was used, which assumes the same homogeneity of effect size across all studies; otherwise, the random-effects model was more appropriate, which tends to provide wider confidence intervals, when the results of the constituent studies differ among themselves. To evaluate the effect of individual studies on the overall risk of cancers, sensitivity analyses were performed by excluding each study individually and recalculating the ORs and 95% CI. Furthermore, a sensitivity analysis was also performed each by excluding three studies whose matching information was unavailable [@pone.0020466-Shen1], [@pone.0020466-Svenson1], [@pone.0020466-Gramatges1], two studies whose DNA were not from blood [@pone.0020466-Broberg1], [@pone.0020466-Hosgood1], and three studies that did not use quantitative PCR to test relative telomere length(T/S ratio) [@pone.0020466-Wu1], [@pone.0020466-Shao1], [@pone.0020466-Zheng1]. The inverted funnel plots and Egger\'s test (linear regression analysis) were used to investigate publication bias [@pone.0020466-Egger1]. All analysis was conducted by using Review Manage (v.5.0) and Stata 10.0. All *P* values were two-sided.

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

As shown in [**Fig. 1**](#pone-0020466-g001){ref-type="fig"}, a total of 146 published records were retrieved by using the key words mentioned earlier in the Methods, of which 26 examined the association between telomere length and cancer risk. Among those 26 publications, five were excluded either because they did not provide available data to extract the ORs and 95% CI [@pone.0020466-Lee1], [@pone.0020466-Zee1], [@pone.0020466-Barwell1], [@pone.0020466-Idei1] or the subjects were of cancer-prone predisposition [@pone.0020466-Risques1]. The remaining 21 publications of case-control studies contained 29 studies (Wu\'s and Pooley\'s studies had datasets of four different cancers and McGrath\'s and Zheng\'s studies had datasets of two different sources) [@pone.0020466-Wu1], [@pone.0020466-McGrath1], [@pone.0020466-Zheng1], [@pone.0020466-Pooley1]. The essential information, including first author, year of publication, country, ethnicity, cancer type, numbers of cases and controls, study type, control source and DNA source for all studies are listed in [**Table 1**](#pone-0020466-t001){ref-type="table"}. Our meta-analysis included nine breast cancer studies [@pone.0020466-Shen1], [@pone.0020466-DeVivo1], [@pone.0020466-Shen2], [@pone.0020466-Gramatges1], [@pone.0020466-Zheng1], [@pone.0020466-Pooley1], four bladder studies [@pone.0020466-Wu1], [@pone.0020466-Broberg1], [@pone.0020466-McGrath1], three lung cancer studies [@pone.0020466-Wu1], [@pone.0020466-Jang1], [@pone.0020466-Hosgood1], two renal cancer studies [@pone.0020466-Wu1], [@pone.0020466-Shao1], two gastric cancers [@pone.0020466-Liu1], [@pone.0020466-Hou1], two colorectal cancers [@pone.0020466-Pooley1] and seven studies of other cancers [@pone.0020466-Wu1], [@pone.0020466-Mirabello1], [@pone.0020466-Xing1], [@pone.0020466-Lan1], [@pone.0020466-Han1], [@pone.0020466-Mirabello2] ([**Table 1**](#pone-0020466-t001){ref-type="table"}). Because some controls in one publication [@pone.0020466-Wu1] were shared by different cancers, it was defined as four studies (head and neck cancer, bladder cancer, lung cancer and renal cell carcinoma) in the analysis stratified by tumor type but defined as one study in the overall analysis and stratification analysis by ethnicity, study type, control source and sample size. Overall, 15 studies used Caucasians, three used Asians, and eight used other ethnic groups; in addition, nine studies were prospective and seventeen were retrospective; 18 studies were population-based, seven were hospital-based, and one was family-based [@pone.0020466-Shen1]. Most of studies provided matching information by age and/or other variables except for three studies [@pone.0020466-Shen1], [@pone.0020466-Svenson1], [@pone.0020466-Gramatges1]. The quantitative PCR was the most frequently used method to measure the relative telomere length (T/S ratio), while three studies used other assays including southern blot telomere restriction fragment (TRF) and quantitative fluorescence in situ hybridization-based approaches (Q-FISH) [@pone.0020466-Wu1], [@pone.0020466-Shao1], [@pone.0020466-Zheng1]. Additionally, the blood was the most common source of DNA, although other sources were also applied, such as buccal cells and sputum [@pone.0020466-Broberg1], [@pone.0020466-Hosgood1].

![Flow chart for the process of selecting the final 21 publications.](pone.0020466.g001){#pone-0020466-g001}

10.1371/journal.pone.0020466.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0020466.t001){#pone-0020466-t001-1}

  Author                                                     Year   Country    Ethnicity           Cancer type           cases/controls    Study type      Control source          DNA source           Measurement methods
  --------------------------------------------------------- ------ --------- ------------- ---------------------------- ---------------- --------------- ------------------ ------------------------- ------------------------
  Wu [@pone.0020466-Wu1]                                     2003     USA      Caucasian       Head and neck cancer          92/92        Retrospective    Hospital-based          Lymphocytes         Southern Blot Analysis
  Wu [@pone.0020466-Wu1] [a](#nt101){ref-type="table-fn"}    2003     USA      Caucasian          Bladder cancer            135/135       Retrospective    Hospital-based          Lymphocytes               Q-FISHLSC
  Wu [@pone.0020466-Wu1] [a](#nt101){ref-type="table-fn"}    2003     USA      Caucasian           Lung cancer               54/54        Retrospective    Hospital-based          Lymphocytes               Q-FISHLSC
  Wu [@pone.0020466-Wu1] [a](#nt101){ref-type="table-fn"}    2003     USA      Caucasian       Renal cell carcinoma          32/32        Retrospective    Hospital-based          Lymphocytes               Q-FISHLSC
  Broberg [@pone.0020466-Broberg1]                           2005   Sweden     Caucasian          Bladder cancer             63/93        Retrospective   Population-based        Buccal cells            Quantitative PCR
  Shen [@pone.0020466-Shen1]                                 2007     USA        Mixed            Breast cancer             283/347       Retrospective     Family-based        White blood cells         Quantitative PCR
  Shao [@pone.0020466-Shao1]                                 2007     USA        Mixed             Renal Cancer              65/65        Retrospective    Hospital-based          Lymphocytes               Q-FISHLSC
  McGrath [@pone.0020466-McGrath1]                           2007     USA     Not defined      Bladder cancer (NHS)          61/67         Prospective    Population-based         Buffy coat             Quantitative PCR
  McGrath [@pone.0020466-McGrath1]                           2007     USA     Not defined     Bladder cancer (HPFS)         123/125        Prospective    Population-based         Buffy coat             Quantitative PCR
  Jang [@pone.0020466-Jang1]                                 2008    Korea       Asian             Lung cancer              243/243       Retrospective    Hospital-based          Whole blood            Quantitative PCR
  Svenson [@pone.0020466-Svenson1]                           2008   Sweden     European           Breast cancer             265/446       Retrospective   Population-based   Buffy coat, granulocyte      Quantitative PCR
  Mirabello [@pone.0020466-Mirabello1]                       2009     USA      Caucasian         Prostate cancer            612/1049       Prospective    Population-based         Buffy coat             Quantitative PCR
  Liu [@pone.0020466-Liu1]                                   2009    China       Asian            Gastric cancer            396/378       Retrospective    Hospital-based          Whole blood            Quantitative PCR
  Xing [@pone.0020466-Xing1]                                 2009     USA      Caucasian        Esophageal cancer            94/92        Retrospective    Hospital-based          Whole blood            Quantitative PCR
  De Vivo [@pone.0020466-DeVivo1]                            2009     USA      Caucasian          Breast cancer             896/917        Prospective    Population-based         Lymphocytes            Quantitative PCR
  Hou [@pone.0020466-Hou1]                                   2009   Poland     Caucasian          Gastric cancer            300/416       Retrospective   Population-based         Lymphocytes            Quantitative PCR
  Shen [@pone.0020466-Shen2]                                 2009     USA        Mixed            Breast cancer            1026/1070      Retrospective   Population-based      Mononuclear cells         Quantitative PCR
  Lan [@pone.0020466-Lan1]                                   2009   Finland    Caucasian       Non-Hodgkin Lymphoma         107/107        Prospective    Population-based         Whole blood            Quantitative PCR
  Han [@pone.0020466-Han1]                                   2009     USA      Caucasian           Skin cancer              740/801        Prospective    Population-based         Buffy coat             Quantitative PCR
  Hosgood [@pone.0020466-Hosgood1]                           2009    China       Asian             Lung cancer               109/97       Retrospective   Population-based           Sputum               Quantitative PCR
  Gramatges [@pone.0020466-Gramatges1]                       2010     USA        Mixed            Breast cancer              102/50       Retrospective   Population-based         Whole blood            Quantitative PCR
  Zheng [@pone.0020466-Zheng1]                               2010     USA        Mixed         Breast cancer (RPC1)         152/176       Retrospective    Hospital-based          Buffy coat             Quantitative PCR
  Zheng [@pone.0020466-Zheng1]                               2010     USA        Mixed         Breast cancer (LCCC)         140/159       Retrospective    Hospital-based          Buffy coat                Q-FISHLSC
  Mirabello [@pone.0020466-Mirabello2]                       2010   Poland     Caucasian          Ovarian cancer             98/100       Retrospective   Population-based         Buffy coat             Quantitative PCR
  Pooley [@pone.0020466-Pooley1]                             2010     UK       Caucasian      Breast cancer (SEARCH)       2243/2181      Retrospective   Population-based            Blood               Quantitative PCR
  Pooley [@pone.0020466-Pooley1]                             2010     UK       Caucasian       Breast cancer (EPIC)         199/420        Prospective    Population-based            Blood               Quantitative PCR
  Pooley [@pone.0020466-Pooley1]                             2010     UK       Caucasian    Colorectal cancer (SEARCH)     2161/2249      Retrospective   Population-based            Blood               Quantitative PCR
  Pooley [@pone.0020466-Pooley1]                             2010     UK       Caucasian     Colorectal cancer (EPIC)       185/406        Prospective    Population-based            Blood               Quantitative PCR
  Prescott [@pone.0020466-Prescott1]                         2010     USA      Caucasian        Endometrial cancer          279/791        Prospective    Population-based            Blood               Quantitative PCR

Some controls were shared. PCR, polymerase chain reaction; Q-FISHLSC, quantitative fluorescence in situ hybridization-based approaches.

Meta-analysis results {#s3b}
---------------------

We obtained the telomere genotyping data from 21 publications consisting of 11,255 cases and 13,101 controls. When all eligible studies were pooled into the meta-analysis, we found that shorter telomeres were significantly associated with the overall cancer risk (OR = 1.35, 95% CI = 1.14--1.60, *P*\<0.001 for heterogeneity test, *I* ^2^ = 88%; [**Fig. 2**](#pone-0020466-g002){ref-type="fig"}). In the stratified analysis by tumor type ([**Table 2**](#pone-0020466-t002){ref-type="table"}), the comparisons showed that individuals with shorter telomeres had an increased risk of bladder cancer (OR = 1.84, 95% CI = 1.38--2.44, *P* = 0.88 for heterogeneity test, *I* ^2^ = 0%) and lung cancer (OR = 2.39, 95% CI = 1.18--4.88, *P* = 0.009 for heterogeneity test, *I* ^2^ = 79%); but not breast cancer (OR = 1.04, 95% CI = 0.77--1.40, *P*\<0.001 for heterogeneity test, *I* ^2^ = 92%). We also found the association between the relative telomere length and overall cancer risk was statistically significant in studies of Caucasian subjects (OR = 1.30, 95% CI = 1.06--1.61, *P*\<0.001 for heterogeneity test, *I* ^2^ = 90%), Asian subjects (OR = 2.08, 95% CI = 1.31--3.30, *P*\<0.001 for heterogeneity test, *I* ^2^ = 75%), retrospective design (OR = 1.44, 95% CI = 1.13--1.84, *P*\<0.001 for heterogeneity test, *I* ^2^ = 86%), hospital-based controls (OR = 2.01, 95% CI = 1.54--2.62, *P* = 0.01 for heterogeneity test, *I* ^2^ = 62%), and sample sizes less than 500 (OR = 1.51, 95% CI = 1.06--2.16, *P*\<0.001 for heterogeneity test, *I* ^2^ = 83%). Furthermore, when cancers were grouped into site-specific types ([**Fig. 3**](#pone-0020466-g003){ref-type="fig"}), the results showed that the association remained significant for smoking-related cancers (OR = 2.25, 95% CI = 1.83--2.78, *P* = 0.07 for heterogeneity test, *I* ^2^ = 54%), cancers in the digestive system (OR = 1.69, 95% CI = 1.53--1.87, *P* = 0.14 for heterogeneity test, *I* ^2^ = 42%) and in the urogenital system (OR = 1.73, 95% CI = 1.12--2.67, *P*\<0.001 for heterogeneity test, *I* ^2^ = 78%).

![Odds ratios (ORs) and 95% confidence intervals (CIs) for overall cancer risk associated with relative telomere length (shorter *vs.* longer, grouped by the median of telomere length ratio).\
^a^ Some controls were shared in the study by Wu *et al* (2003) that included a total of 313 cases and 256 controls.](pone.0020466.g002){#pone-0020466-g002}

![Odds ratios (ORs) and 95% confidence intervals (CIs) for risk of different cancers associated with relative telomere length (shorter *vs.* longer, grouped by median value of telomere length ratio).\
(**A**) Smoking-related cancers; (**B**) Cancers in the digestive system; (**C**) Cancers in the urogenital system.](pone.0020466.g003){#pone-0020466-g003}

10.1371/journal.pone.0020466.t002

###### Associations between relative telomere length and cancer risk stratified by selected factors.

![](pone.0020466.t002){#pone-0020466-t002-2}

  Variables             No of studies [a](#nt102){ref-type="table-fn"}      Sample       Shorter *vs.* longer   *P* for Heterogeneity  
  -------------------- ------------------------------------------------ --------------- ---------------------- ----------------------- -----------
  **All**                                     26                         11,255/13,101    1.35 (1.14--1.60)       1.37 (1.30--1.44)     \<0.00001
  **Tumor type**                                                                                                                       
  Breast cancer                               9                           5,306/5,766     1.04 (0.77--1.40)       1.29 (1.20--1.40)     \<0.00001
  Bladder cancer                              4                             382/420       1.83 (1.38--2.44)       1.84 (1.38--2.44)       0.88
  Lung cancer                                 3                             406/394       2.39 (1.18--4.88)       2.44 (1.82--3.27)       0.009
  Other                                       13                          5,161/6,578     1.47 (1.15--1.87)       1.37 (1.27--1.47)     \<0.00001
  **Ethnicity**                                                                                                                        
  Caucasian                                   15                         8,555/10,324     1.30 (1.06--1.61)       1.38 (1.30--1.46)     \<0.00001
  Asian                                       3                             748/718       2.08 (1.31--3.30)       2.20 (1.78--2.72)     \<0.00001
  Other                                       8                           1,952/2,059     1.21 (0.87--1.70)       1.11 (0.98--1.26)     \<0.00001
  **Study type**                                                                                                                       
  Prospective                                 9                           7,222/8,287     1.21 (0.93--1.57)       1.39 (1.30--1.48)     \<0.00001
  Retrospective                               17                          4,033/4,814     1.44 (1.13--1.84)       1.33 (1.22--1.45)     \<0.00001
  **Control Source**                                                                                                                   
  Hospital                                    7                           1,403/1,369     2.01 (1.54--2.62)       2.03 (1.74--2.36)       0.01
  Population                                  18                         9,569/11,385     1.18 (0.96--1.43)       1.30 (1.23--1.38)     \<0.00001
  **Sample size**                                                                                                                      
  \<500                                       13                          1,670/1,630     1.51 (1.06--2.16)       1.61 (1.40--1.85)     \<0.00001
  500--1000                                   6                           1,628/2,413     1.30 (0.91--1.86)       1.31 (1.15--1.49)     \<0.00001
  \>1000                                      7                           7,957/9,058     1.18 (0.91--1.53)       1.34 (1.26--1.42)     \<0.00001

Some controls in the publication by Wu (2003) *et al* were shared by different cancers; therefore, it was defined as four studies (head and neck cancer, bladder cancer, lung cancer and renal cell carcinoma) in the analysis stratified by tumor type, but defined as one study in the analysis stratified by study type, ethnicity and source of controls. In addition, the publication by Shen (2007) *et al* was family-based and excluded from the analysis for source of controls.

Random effects model.

Fixed effects model.

Heterogeneity and sensitivity analyses {#s3c}
--------------------------------------

Substantial heterogeneity was observed among all studies for the relative telomere length and cancer risk (χ^2^ = 215.43, *P*\<0.001, [**Fig. 2**](#pone-0020466-g002){ref-type="fig"}). Therefore, we evaluated the source of heterogeneity by tumor type, ethnicity, control source, study type and sample size, and we found that tumor type and control source did contribute to substantial heterogeneity (χ^2^ = 9.33, *P* = 0.025 for tumor type and χ^2^ = 9.88, *P* = 0.002 for control source, respectively) but not from ethnicity (χ^2^ = 3.90, *P* = 0.143), study type (χ^2^ = 0.91, *P* = 0.340) and sample size (χ^2^ = 1.21, *P* = 0.547). The leave-one-out sensitivity analysis indicated that no single study changed the pooled ORs qualitatively (data not shown). Furthermore, the sensitivity analysis without three studies whose matching information was unavailable [@pone.0020466-Shen1], [@pone.0020466-Svenson1], [@pone.0020466-Gramatges1], two studies whose DNA were not from blood [@pone.0020466-Broberg1], [@pone.0020466-Hosgood1], or three studies without use of quantitative PCR to test relative telomere length (T/S ratio) [@pone.0020466-Wu1], [@pone.0020466-Shao1], [@pone.0020466-Zheng1] did not alter the results of the meta-analysis (OR = 1.48, 95% CI = 1.26--1.74, *P*\<0.001 for heterogeneity test, *I* ^2^ = 87%; OR = 1.34, 95% CI = 1.12--1.59, *P*\<0.001 for heterogeneity test, *I* ^2^ = 89%; and OR = 1.30, 95% CI = 1.08--1.55, *P*\<0.001 for heterogeneity test, *I* ^2^ = 89%; respectively).

Publication bias {#s3d}
----------------

As shown in [**Fig. 4**](#pone-0020466-g004){ref-type="fig"}, the shapes of the funnel plots seemed symmetrical, and Egger\'s test suggested that there was no publication bias in the current meta-analysis (*P* = 0.532). These indicated that bias from publications might not have a significant influence on the results of our meta-analysis on the association between telomere length and cancer risk.

![Funnel plot analysis to detect publication bias.\
Each point represents an independent study for the indicated association.](pone.0020466.g004){#pone-0020466-g004}

Discussion {#s4}
==========

In this meta-analysis of 11,255 cancer cases and 13,101 controls from 21 independent publications, we found that shorter telomeres were significantly associated with risk of cancer, especially cancers of the bladder and lung, smoking-related, the digestive system and the urogenital system. Furthermore, the stratification analysis also showed that the association was more prominent in studies of Caucasian subjects, Asian subjects, retrospective design, hospital-based controls, and smaller sample sizes.

Studies have showed that telomeres are critical for maintaining genomic integrity and that telomere dysfunction or shortening is an early, common genetic alteration acquired in the multistep process of malignant transformation [@pone.0020466-Blasco1], [@pone.0020466-Raynaud1]. In addition, telomere dysfunction has been found to be associated with decreased DNA repair capacity and complex cytogenetic abnormalities [@pone.0020466-Wong1]. Both of animal studies and clinical observations have shown that shorter telomeres were associated with increased risk of cancers, such as epithelial cancers [@pone.0020466-Artandi2], [@pone.0020466-Kim1], [@pone.0020466-Sommerfeld1]. However, telomere shortening might play conflicting roles in cancer development. For example, the progressive loss of telomeric repeats with each cell division can induce replicative senescence and limit the proliferative potential of a cell, thus functioning as a tumor suppressor [@pone.0020466-Blasco1], [@pone.0020466-Stewart1]. But, once telomeres reach a critical length, it will result in chromosome break, causing genome instability and enhancing potential for malignant transformation via fusion-bridge-breakage cycles [@pone.0020466-Capper1]. In this meta-analysis, we found that shorter telomeres were significantly associated with cancer risk, supporting the hypothesis that excessive telomere shortening may play a role in accelerating tumor onset and progression.

Although this meta-analysis showed significant associations between shorter telomeres and overall cancer risk, some results from stratification analysis remind us of drawing the conclusion with caution. The stratification analysis by tumor type showed that the association between shorter telomeres and cancer risk was significant in bladder cancer, lung cancer, smoking-related cancers, and cancers in the digestive system and in the urogenital system, but not in breast cancer. Because our heterogeneity analysis also showed that tumor type did contribute to substantial heterogeneity, these inconsistent results by cancer types may involve different carcinogenic mechanisms conferred by specific telomeres in specific cancer types. Different biological pathways (such as metabolisms of hormone, tobacco carcinogens and repair of DNA damage) could interact with telomere length, resulting in different efforts on cancer susceptibility. For example, several studies found that the effect of shortened telomeres on breast cancer risk was significant for certain subgroups, such as premenopausal women and women with a poor antioxidative capacity [@pone.0020466-Shen2] but not for the overall study population [@pone.0020466-Shen2], [@pone.0020466-Zheng1]or postmenopausal women[@pone.0020466-DeVivo1]. The possible explanation may be that the difference in hormones, particularly estrogen, may affect telomere dynamics through its antioxidant attributes and its ability to stimulate telomerase, which can elongate telomere ends [@pone.0020466-Blackburn2]. In addition, it has been reported that short telomeres on specific chromosome arms may be more important for cancer risk than the overall telomere length in a cell, and chromosome arms with the shortest telomeres were more often found in the telomere fusions, leading to chromosome instability [@pone.0020466-Hemann1], [@pone.0020466-derSarkissian1]. For breast cancer, frequent chromosomal abnormalities mainly occur on certain chromosome arms, such as gains of 1q, 8q, 17q, and 20q, and losses of 8p, 9p, 16q, and 17p [@pone.0020466-Baudis1], [@pone.0020466-Gorgoulis1], [@pone.0020466-An1]. Thus, different associations between overall telomere length and risk of different cancers may due to the confounding effect of large number of "irrelevant" telomeres in the measurement.

Furthermore, the results from stratification analysis by other factors, including study type, control source and sample size, indicated that the association was more prominent in studies with retrospective designs, hospital-based controls and smaller sample sizes. However, these studies suffer from several major drawbacks, such as information bias, selection bias and lower statistical power, which may have a substantial influence on the results of studies per se and thus on our meta-analysis as well. Specially, the difference between studies with retrospective designs (random effects model: OR = 1.44, 95% CI = 1.13--1.84; heterogeneity *P*\<0.0001) and prospective designs (random effects model: OR = 1.21, 95% CI = 0.93--1.57; heterogeneity *P*\<0.0001) suggests possible biases in those studies with retrospective designs. The majority of published studies on telomere length and cancer risk were retrospective case-control studies in which DNA samples from the cases were collected after cancer diagnosis. This could potentially result in reverse causation bias, where changes in surrogate tissue telomere length may be a consequence of the cancer rather than a cause. Recently, a study by Nordfjäll *et al* [@pone.0020466-Nordfjall1] evaluated the blood telomere length in 959 individuals at baseline and after 10 years of follows-up, and they found no differences in telomere length (at baseline or at follow up) between controls and those who later were diagnosed with cancer, which may challenge the hypothesis that individual telomere length can predict later tumor development. Therefore, the findings of an association between shorter telomeres and cancer risk in this meta-analysis still require further replication in single large prospective studies that avoid or carefully address potential biases.

Limitations {#s4a}
-----------

Some other issues in this meta-analysis also need to be addressed. Firstly, several variables may affect the length of telomeres, such as age, sex, obesity, smoking, oxidative stress and chronic inflammation [@pone.0020466-Blasco1], [@pone.0020466-Epel1], [@pone.0020466-Valdes1], [@pone.0020466-vonZglinicki3]. However, the results of this meta-analysis were based on unadjusted estimates, because either ORs derived from different studies were not adjusted by the same potential confounders or only the number of cases and controls was provided without the detailed information of other variables. In fact, we did try to calculate the summary ORs using adjusted ORs available from only nine original papers [@pone.0020466-Shen1], [@pone.0020466-Jang1], [@pone.0020466-Mirabello1], [@pone.0020466-Liu1], [@pone.0020466-Xing1], [@pone.0020466-DeVivo1], [@pone.0020466-Shen2], [@pone.0020466-Zheng1], [@pone.0020466-Prescott1], and we found that there were no substantial changes in the pooled, adjusted ORs (OR = 1.41, 95% CI = 1.10--1.82, *P*\<0.001 for heterogeneity test, *I* ^2^ = 82.9%). Further, there is some evidence that treatment status (chemotherapy or radiation) can alter telomere length [@pone.0020466-Fern1], [@pone.0020466-Unryn1], and we cannot rule out the possibility of such an effect because of unavailable information about the disease treatment status from the studies used in the analysis. A more precise analysis should be conducted, if individual data were available, allowing for the adjustment by some co-variants and excluding those patients who had been treated. Secondly, various methods were used to measure the relative telomere length in those studies used in our meta-analysis, including southern blot, Q-FISH and Q-PCR assays, which made it difficult to directly compare or pool data from different studies. Thirdly, the association between telomere length and cancer risk may be affected by the types of surrogate tissues. In studies included in this meta-analysis, DNA from multiple sources was used, including blood, buccal cells and sputum ([**Table 1**](#pone-0020466-t001){ref-type="table"}). Although the majority of the inter-individual variation in telomere length may be genetically determined [@pone.0020466-Slagboom1], and cells with different origins show a good intra-individual correlation for telomere length in healthy subjects and case subjects [@pone.0020466-Friedrich1], [@pone.0020466-Gadalla1], it may be disputable for the use of hematopoietic cells to be a proxy of average individual telomere length, because the variation in telomere length has been observed within leukocyte subsets but not others [@pone.0020466-VanZiffle1]. Therefore, consistent measurement methods and use of the surrogate tissues are warranted in further studies on telomere length, which may provide comparable data from different studies.

Conclusions {#s4b}
-----------

Our meta-analysis provided statistical evidence for an association between shorter telomere length and risk of human cancer, particularly for bladder cancer, lung cancer, smoking-related cancers, and cancers in the digestive system and in the urogenital system. However, due to the limitations of original studies included in the meta-analyses, larger, well-designed prospective studies are needed to confirm these findings, which may help unravel the underlying mechanisms of telomere shortening in cancer development and progression.
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